<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01654315</url>
  </required_header>
  <id_info>
    <org_study_id>2011H0215</org_study_id>
    <nct_id>NCT01654315</nct_id>
  </id_info>
  <brief_title>Robotic Brace Incorporating Electromyography for Moderate Affected Arm Impairment After Stroke</brief_title>
  <official_title>Robotic Brace Incorporating EMG for Moderate Affected Arm Impairment After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Of the 5.7 million stroke survivors in the United States, up to 80% exhibit significant&#xD;
      weakness in one arm (called &quot;hemiparesis&quot;). This devastating impairment undermines&#xD;
      performance of valued activities and quality of life. Although rehabilitation is commonly&#xD;
      provided, conventional affected arm rehabilitative strategies have negative evidence, or no&#xD;
      evidence, supporting their use. Thus, there remains a need for evidence-based rehabilitative&#xD;
      strategies for arm hemiparesis.&#xD;
&#xD;
      Newer rehabilitative approaches emphasize repetitive, task-specific practice (RTP)&#xD;
      incorporating the affected arm. However, many of these promising regimens require&#xD;
      participation in intensive therapies, and most are only efficacious on the least impaired&#xD;
      patients. Thus, there remains a need for an efficacious, practical RTP technique to address&#xD;
      moderate affected arm hemiparesis.&#xD;
&#xD;
      To address the above shortfalls, one of the investigators team members piloted an innovative&#xD;
      brace integrating electromyography (EMG) and robotics. In his case series, 8 stroke patients&#xD;
      exhibiting moderate arm impairment successfully participated in RTP, with the brace (called&#xD;
      the &quot;Myomo&quot;) detecting and augmenting their movement attempts. Aided by the Myomo,&#xD;
      participation in the RTP regimen reduced subjects' affected arm impairment and spasticity.&#xD;
      The next logical step is to test Myomo + RTP efficacy using randomized controlled methods and&#xD;
      an appropriate sample size.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this small efficacy study is to collect randomized, controlled pilot&#xD;
      data estimating clinical effectiveness of this combined, EMG/robotics approach in conjunction&#xD;
      with RTP. A unique adjunct will be acquisition of biomechanical data as an outcome measure.&#xD;
      Based on pilot data, the central hypothesis is that Myomo therapy with RTP will exhibit&#xD;
      significant impairment reductions. We will test the central hypothesis and accomplish the&#xD;
      objective by pursuing the following specific aims:&#xD;
&#xD;
      Specific Aim 1: Compare efficacy of Myomo + RTP with RTP only and Myomo only on affected arm&#xD;
      impairment. Thirty stroke patients exhibiting moderate affected arm deficits will be randomly&#xD;
      assigned to receive: (a) Myomo combined with RTP (Myomo + RTP); (b) RTP only (RTP), which&#xD;
      constitutes the most frequently used regimen in clinical environments;2,3 or (c) Myomo&#xD;
      therapy only (Myomo). The current study design will determine the additive effect of Myomo&#xD;
      training to RTP, while also discerning the relative efficacy of RTP only or Myomo use only.&#xD;
      The intended duration of contact will be equivalent across groups.&#xD;
&#xD;
      Affected arm impairment, the primary study outcome, will be measured by the upper extremity&#xD;
      section of the Fugl-Meyer Impairment Scale (FM), the primary outcome measure. The FM will be&#xD;
      administered by a blinded rater twice before intervention, immediately post-intervention&#xD;
      (POST), and two months post-intervention (POST-2) with POST serving as the primary study&#xD;
      endpoint. The primary study hypothesis is that subjects in the Myomo + RTP group will exhibit&#xD;
      significantly larger FM score changes than Myomo or RTP subjects at POST. It is also&#xD;
      hypothesized that these changes will be sustained at POST-2.&#xD;
&#xD;
      Specific Aim 2: Determine the impact of Myomo + RTP on affected arm outcomes. The&#xD;
      investigators will administer the Arm Motor Ability Test (AMAT), to all subjects before&#xD;
      intervention, at POST, and at POST-2. When compared to their scores before intervention, it&#xD;
      is hypothesized that Myomo + RTP subjects will exhibit significantly larger AMAT score&#xD;
      changes,than subjects in the other groups at POST. These differences will be sustained at&#xD;
      POST-2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impairment in the Affected Upper Extremity as Measured by the Fugl Meyer Scale.</measure>
    <time_frame>Administered twice before the intervention period. These two scores are averaged to provide a composite score that is compared to average score for each group that is collected 1 week after intervention</time_frame>
    <description>The upper extremity section of the Fugl-Meyer Scale (FM) will assess whether changes occur in paretic upper extremity motor impairment. The FM has been used extensively in stroke recovery studies, and is highly recommended for &quot;use in clinical trials designed to evaluate changes in motor impairment following stroke.&quot; The items on the measure require the subject to perform various movements with the affected upper extremity, and each item is scored from 0 (cannot perform) to 2 (performs normally). Item are then summed for a total score. The total score ranges are 0 to 66, with a higher score representing less upper extremity impairment (and, thus, a relatively &quot;better&quot; score on the measure than a lower score).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arm Motor Ability Test (AMAT)</measure>
    <time_frame>Administered twice before the intervention period. These two scores are averaged to provide a composite score that is compared to average score for each group that is collected 1 week after intervention</time_frame>
    <description>The Arm Motor Activity Test (AMAT) was the secondary outcome for this study and was used to determine whether changes occur in activity limitation. The AMAT is a 13-item test in which valued activities are rated according to a functional ability scale that examines affected limb use 0 = no use, 1 = very slight use, 2 = slight use, 3 = moderate use, 4 = almost normal use, 5 = normal use;) and a Quality of Movement Scale (0 = no use, 1 = very poor, 2 = poor, 3 = fair, 4 = almost normal, 5 = normal. ). Therefore, the highest score that one can attain on either scale is 65.0 (which would mean that the person scored a perfect score of &quot;5&quot; on each of the thirteen items).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Hemiparesis</condition>
  <arm_group>
    <arm_group_label>Experimental: Myomo Only Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Myomo Only Group Patients are administered rehabilitative therapy known as &quot;repetitive task specific practice&quot; (RTP) using only the Myomo robotic device targeting their affected arms on 3 days/week, in 1/2 hour increments, during an 8-week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Myomo + RTP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week in 1/2 hour increments, during an 8 week period. These patients engage in activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the device during the activities is reduced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: RTP Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Myomo Robotic Arm</intervention_name>
    <description>Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as &quot;RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion.</description>
    <arm_group_label>Experimental: Myomo + RTP Group</arm_group_label>
    <arm_group_label>Experimental: Myomo Only Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>RTP Standard Therapy</intervention_name>
    <description>Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.</description>
    <arm_group_label>Active Comparator: RTP Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  upper extremity Fugl Meyer score &gt;10-&lt; 25 (i.e., subject must score between (and&#xD;
             including) 10 and 25 on the UE FM at the baseline screening appointment only)&#xD;
&#xD;
          -  presence of volitionally activated EMG signal from the paretic biceps brachii of at&#xD;
             least 5 Å³V in amplitude&#xD;
&#xD;
          -  stroke experienced &gt; 1 month prior to study enrollment&#xD;
&#xD;
          -  a score &gt; 24 on the Folstein Mini Mental Status Examination (MMSE)&#xD;
&#xD;
          -  age &gt; 35 &lt; 85&#xD;
&#xD;
          -  have experienced one stroke&#xD;
&#xD;
          -  discharged from all forms of physical rehabilitation&#xD;
&#xD;
          -  Myomo brace fits on affected arm properly and without discomfort (i.e., no red marks&#xD;
             or discomfort observed in 10 minutes of use during fitting).&#xD;
&#xD;
          -  &lt; 35 years old&#xD;
&#xD;
          -  excessive pain in the affected hand, arm or shoulder, as measured by a score &gt; 5 on a&#xD;
             10-point visual analog scale&#xD;
&#xD;
          -  excessive spasticity at the affected elbow, as defined as a score of &gt; 4 on the&#xD;
             Modified Ashworth Spasticity Scale&#xD;
&#xD;
          -  currently participating in any experimental rehabilitation or drug studies&#xD;
&#xD;
          -  apraxia (&lt; 2.5 on the Alexander scale)&#xD;
&#xD;
          -  severe sensory loss in affected hand (Nottingham sensory scale at least 75% of normal)&#xD;
&#xD;
          -  severe language deficits (score &lt; 2 on NIH Stroke Scale question 9)&#xD;
&#xD;
          -  Stroke that occurred in the brainstem (corticospinal tracts are the final pathway for&#xD;
             the motor system, and are frequently damaged in brainstem strokes. These individuals&#xD;
             are hypothesized to be less likely to benefit from the cortical plasticity seen with&#xD;
             exercise therapy, and are therefore excluded from this study.)&#xD;
&#xD;
          -  A current medical history of uncontrolled cardiovascular, or pulmonary disease, or&#xD;
             other disease that would preclude involvement in a therapeutic treatment (Subjects&#xD;
             must be able to tolerate a one-hour upper-extremity therapy session.)&#xD;
&#xD;
          -  History of neurological disorder other than stroke (other neurological disorders may&#xD;
             affect the upper extremity motor performance of subjects.); (11) Other significant&#xD;
             pain or skin irritation in the upper extremity that would be exacerbated if by the use&#xD;
             of the brace (While wearing the brace, the system is pressed close to the upper arm&#xD;
             and strapped around it. (If the subject suffers from dermal breakdown or other skin&#xD;
             conditions that may be aggravated by such a situation, they should not be involved in&#xD;
             the study.)&#xD;
&#xD;
          -  Substantial contracture of elbow, defined as &gt; 20 degrees of elbow flexion, as&#xD;
             measured at the baseline evaluation. (The system cannot work in the presence of&#xD;
             reduced range of motion due to contractures.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Page, PhD,M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <results_first_submitted>February 19, 2017</results_first_submitted>
  <results_first_submitted_qc>May 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2019</results_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>STEPHEN PAGE</investigator_full_name>
    <investigator_title>Associate Professor School of Health and Rehabilitation Sciences Division of Occupational Therapy Affiliation: Ohio State University</investigator_title>
  </responsible_party>
  <keyword>RTP Only Group</keyword>
  <keyword>Myomo Only Group</keyword>
  <keyword>Myomo + RTP Group</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paresis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental: Myomo Only Group</title>
          <description>Experimental: Myomo Only Group Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
        </group>
        <group group_id="P2">
          <title>Experimental: Myomo + RTP Group</title>
          <description>Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
        </group>
        <group group_id="P3">
          <title>Active Comparator: RTP Group</title>
          <description>Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental: Myomo Only Group</title>
          <description>Experimental: Myomo Only Group Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
        </group>
        <group group_id="B2">
          <title>Experimental: Myomo + RTP Group</title>
          <description>Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
        </group>
        <group group_id="B3">
          <title>Active Comparator: RTP Group</title>
          <description>Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.69" spread="8.6"/>
                    <measurement group_id="B2" value="52.28" spread="13.0"/>
                    <measurement group_id="B3" value="57.22" spread="7.7"/>
                    <measurement group_id="B4" value="54.9" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Impairment in the Affected Upper Extremity as Measured by the Fugl Meyer Scale.</title>
        <description>The upper extremity section of the Fugl-Meyer Scale (FM) will assess whether changes occur in paretic upper extremity motor impairment. The FM has been used extensively in stroke recovery studies, and is highly recommended for &quot;use in clinical trials designed to evaluate changes in motor impairment following stroke.&quot; The items on the measure require the subject to perform various movements with the affected upper extremity, and each item is scored from 0 (cannot perform) to 2 (performs normally). Item are then summed for a total score. The total score ranges are 0 to 66, with a higher score representing less upper extremity impairment (and, thus, a relatively &quot;better&quot; score on the measure than a lower score).</description>
        <time_frame>Administered twice before the intervention period. These two scores are averaged to provide a composite score that is compared to average score for each group that is collected 1 week after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Myomo Only Group</title>
            <description>Experimental: Myomo Only Group Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Myomo + RTP Group</title>
            <description>Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
          </group>
          <group group_id="O3">
            <title>Active Comparator: RTP Group</title>
            <description>Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Impairment in the Affected Upper Extremity as Measured by the Fugl Meyer Scale.</title>
          <description>The upper extremity section of the Fugl-Meyer Scale (FM) will assess whether changes occur in paretic upper extremity motor impairment. The FM has been used extensively in stroke recovery studies, and is highly recommended for &quot;use in clinical trials designed to evaluate changes in motor impairment following stroke.&quot; The items on the measure require the subject to perform various movements with the affected upper extremity, and each item is scored from 0 (cannot perform) to 2 (performs normally). Item are then summed for a total score. The total score ranges are 0 to 66, with a higher score representing less upper extremity impairment (and, thus, a relatively &quot;better&quot; score on the measure than a lower score).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="3.8"/>
                    <measurement group_id="O2" value="18.0" spread="5.9"/>
                    <measurement group_id="O3" value="17.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm Motor Ability Test (AMAT)</title>
        <description>The Arm Motor Activity Test (AMAT) was the secondary outcome for this study and was used to determine whether changes occur in activity limitation. The AMAT is a 13-item test in which valued activities are rated according to a functional ability scale that examines affected limb use 0 = no use, 1 = very slight use, 2 = slight use, 3 = moderate use, 4 = almost normal use, 5 = normal use;) and a Quality of Movement Scale (0 = no use, 1 = very poor, 2 = poor, 3 = fair, 4 = almost normal, 5 = normal. ). Therefore, the highest score that one can attain on either scale is 65.0 (which would mean that the person scored a perfect score of &quot;5&quot; on each of the thirteen items).</description>
        <time_frame>Administered twice before the intervention period. These two scores are averaged to provide a composite score that is compared to average score for each group that is collected 1 week after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Myomo Only Group</title>
            <description>Experimental: Myomo Only Group Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Myomo + RTP Group</title>
            <description>Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
          </group>
          <group group_id="O3">
            <title>Active Comparator: RTP Group</title>
            <description>Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm Motor Ability Test (AMAT)</title>
          <description>The Arm Motor Activity Test (AMAT) was the secondary outcome for this study and was used to determine whether changes occur in activity limitation. The AMAT is a 13-item test in which valued activities are rated according to a functional ability scale that examines affected limb use 0 = no use, 1 = very slight use, 2 = slight use, 3 = moderate use, 4 = almost normal use, 5 = normal use;) and a Quality of Movement Scale (0 = no use, 1 = very poor, 2 = poor, 3 = fair, 4 = almost normal, 5 = normal. ). Therefore, the highest score that one can attain on either scale is 65.0 (which would mean that the person scored a perfect score of &quot;5&quot; on each of the thirteen items).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.21" spread="8.67"/>
                    <measurement group_id="O2" value="28.62" spread="8.38"/>
                    <measurement group_id="O3" value="25.33" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental: Myomo Only Group</title>
          <description>Experimental: Myomo Only Group Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
        </group>
        <group group_id="E2">
          <title>Experimental: Myomo + RTP Group</title>
          <description>Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
        </group>
        <group group_id="E3">
          <title>Active Comparator: RTP Group</title>
          <description>Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period.&#xD;
Myomo Robotic Arm: Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stephen Page</name_or_title>
      <organization>The Ohio State University</organization>
      <phone>614-292-5490 ext 614</phone>
      <email>STEPHEN.PAGE@OSUMC.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

